Merck To Incorporate Idera’s TLR Agonists Into Vaccine Program

Merck will pay Idera $20 million up front as part of deal.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet